logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

The Beginning of a Nektar Outperformance?

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics ( NKTR ) and Bristol-Myers Squibb ( BMY ) announced their agreement for a new joint development plan aimed at advancing the combination of Nektar's bempegaldesleukin (bempeg) + Bristol-Myers’ Opdivo (nivolumab) into...

Read More

January 11, 2020

0

Exelixis: The FDA Approved Cabometyx in Combination with Opdivo as a First Line Treatment of RCC

Exelixis: FDA Approval for Cabometyx in Combination with Opdivo  Exelixis ( EXEL ) announced that the United States FDA has approved CABOMETYX (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for patients with advanced renal cell carcinoma ( RCC...

Read More

January 23, 2021

0

Moderna COVID-19 Vaccine Produced Neutralizing Titers Against Key Emerging Variants Tested

Moderna COVID-19 Vaccination News A vaccination with the Moderna ( MRNA ) COVID-19 produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and the Republic of South Africa, respectively. The study...

Read More

January 28, 2021

0

Why Moderna Stock Is Boosted in Today's Bad Stock Market Day

Coronavirus On January 7, 2020, a novel coronavirus ( 2019-nCoV ) was identified in humans in Wuhan City, Hubei Province, China. Additional cases have been found in the United States and in a growing number of countries around the world....

Read More

January 27, 2020

0

Researchers at the Children’s Hospital of Philadelphia are Improving Gene Therapy Vectors

The Children's Hospital of Philadelphia: Improving Gene Therapy Vectors Improving gene therapy vectors seems to have come at the hands of researchers at Children’s Hospital of Philadelphia ( CHOP ). A gene therapy vector was developed for blood disorders like...

Read More

February 5, 2021

0

ADC Therapeutics: Moving from a Development-Stage Firm to a Revenue-Generating Firm

ADC Therapeutics First Quarter Financial Results and Business Updates ADC Therapeutics SA ( ADCT ) is a commercial-stage biotechnology company that creates novel antibody-drug conjugates ( ADCs ) for the treatment of hematological malignancies and solid tumors.   Today, ADC Therapeutics...

Read More

May 7, 2021

0

Vir Biotechnology and GlaxoSmithKline Expanded Agreement

Vir Biotechnology and GlaxoSmithKline Expanded Collaboration  Vir Biotechnology ( VIR ) and GlaxoSmithKline plc ( GSK ) announced the signing of a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza...

Read More

February 17, 2021

0

Novavax is Bringing its COVID-19 Vaccine to the World’s Markets

Novavax Inc The Novavax ( NVAX ) COVID-19 Vaccine NVX-CoV2373 is on its way to reaching worldwide markets.  The Serum Institute of India ( SII ) and the Vaccine Alliance ( Gavi ) are to ensure equitable access to Novavax's, NVX-CoV2373, vaccine...

Read More

February 19, 2021

0

Cassava Sciences: Good News During Bad Market Days

The market is sinking in a furious mood caused by the failure to figure out the pathway of criteria, which is currently controlling the stocks’ volatile performances. Today we are posting good news coming from a few biotech companies with...

Read More

February 23, 2021

0

Reata Pharmaceuticals: Good News from the FDA Regarding Omaveloxolone for Friedreich’s Ataxia

Reata Pharmaceuticals Good News Reata Pharmaceuticals ( RETA ) announced it received a communication from the Division of Neurology Products of the U.S. FDA stating, that after a preliminary review of briefing materials for an upcoming Type C meeting, a...

Read More

May 19, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 91
  • 92
  • 93
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy